Major US weight-loss drug manufacturers are reducing prices for medicines like Zepbound as they compete to attract customers and make treatments more affordable.

Following the expiration of Novo's patent, Indian drugmakers are set to sell a copy of the diabetes and weight-loss drug Ozempic for approximately $14 a month, significantly cheaper than the original.

Drugmakers are re-evaluating their strategies in Europe as the Trump administration implements significant overhauls to drug-pricing regulations in the United States.

International pharmaceutical companies are expanding their operations and presence in the United States, a strategic move influenced by the looming threat of tariffs.

Global drugmakers rush to boost US presence as tariff threat looms  TradingView

Drugmakers are delaying some European product launches, closely monitoring potential impacts from former President Trump's proposed pricing policies.

The generic drugmakers, with many more expected to make announcements, are eyeing a share of the market for Semaglutide in India, which is estimated to be $1 billion over the next couple of years

The ‌probe could lead to import duties, higher costs for drugmakers and agrochemical firms while shielding local producers if dumping is confirmed

Unease centered around the Iran war is keeping Korean drugmakers and health device companies on their toes amid growing concerns over supply chains and exports. The Korea Pharmaceutical and Bio-Pharma Manufacturers Association has warned that product supply schedules could be disrupted if the conflict in the Middle East leads to reduced flights, altered flight routes or closed airways. Delayed payments could also pose risks for companies, the business lobby said. “Disposable culture bags, filter

Doctors are worried about the FDA's scrutiny of RSV antibody shots, which are about 80% effective in preventing severe RSV in infants, while drugmakers maintain their safety.

Weight-loss drug manufacturers in the United States are reducing prices as they compete to attract more customers in a growing market.

New disclosures show how pharma groups reduced federal levies last year by assigning profits to low-tax jurisdictions

Big drugmakers must face US overcharge claims on medications for low-income patients Reuters

Upcoming reforms targeting Pharmacy Benefit Managers (PBMs) are anticipated to shift the focus onto drugmakers, potentially increasing pressure on them regarding drug pricing strategies.